Last reviewed · How we verify
Civacir® 10%
Civacir is a hepatitis C immunoglobulin (HCV-IG) that provides passive immunity by supplying antibodies against hepatitis C virus to prevent reinfection in transplant recipients.
Civacir is a hepatitis C immunoglobulin (HCV-IG) that provides passive immunity by supplying antibodies against hepatitis C virus to prevent reinfection in transplant recipients. Used for Prevention of hepatitis C virus reinfection in HCV-positive patients undergoing orthotopic liver transplantation.
At a glance
| Generic name | Civacir® 10% |
|---|---|
| Also known as | Civacir®, Hepatitis C Immune Globulin Intravenous (Human), human polyclonal immune globulin (IgG), HCIg |
| Sponsor | Biotest Pharmaceuticals Corporation |
| Drug class | Hepatitis C immunoglobulin (HCV-IG) |
| Target | Hepatitis C virus (HCV) envelope proteins |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Civacir contains pooled human immunoglobulin with high titers of antibodies against hepatitis C virus. It is administered intravenously to HCV-positive patients undergoing liver transplantation to neutralize circulating HCV virions and reduce the risk of graft reinfection. The antibodies bind to viral particles and prevent them from infecting the newly transplanted liver.
Approved indications
- Prevention of hepatitis C virus reinfection in HCV-positive patients undergoing orthotopic liver transplantation
Common side effects
- Infusion-related reactions
- Headache
- Fever
- Chills
- Back pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Civacir® 10% CI brief — competitive landscape report
- Civacir® 10% updates RSS · CI watch RSS
- Biotest Pharmaceuticals Corporation portfolio CI